Muhammad Ishaq
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Muhammad Ishaq has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Vanni Caruso
University of Tasmania
8 shared publications - Tauseef Ahmad
School of Health Sciences, University of Tasmania, Launceston, TAS 7248, Australia
5 shared publications - Rajaraman Eri
School of Science, STEM College, RMIT University, Melbourne, Australia
4 shared publications - Maurizio Ronci
Department of Medical, Oral and Biotechnological Sciences, University G. d’Annunzio of Chieti-Pescara, 66100 Chieti, Italy
3 shared publications - Ah Young Park
Marinova Pty Ltd., Cambridge, TAS 7170, Australia
2 shared publications Cameron Randall
School of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS, Australia
2 shared publications
Latest Publications
- Open Access
- 24 May 2023
- Published by MDPI AG in Nutraceuticals
- Vol. 3 (2) , 262-273
Twelve Weeks of Oral L-Serine Supplementation Improves Glucose Tolerance, Reduces Visceral Fat Pads, and Reverses the mRNA Overexpression of Renal Injury Markers KIM-1, IL-6, and TNF-α in a Mouse Model of Obesity
Comorbidities associated with obesity, including diabetes and kidney diseases, greatly increase mortality rates and healthcare costs in obese patients. Studies in animal models and clinical trials have demonstrated that L-serine supplementation is a safe and effective therapeutic approach that ameliorates the consequences of obesity. However, little is known about the effects of L-Serine supplementation following high-fat diet (HFD) consumption and its role in the mRNA expression of markers of kidney injury. We provide a descriptive action by which L-serine administration ameliorated the consequences of HFD consumption in relation to weight loss, glucose homeostasis as well as renal mRNA expression of markers of kidney injury. Our results indicated that L-Serine supplementation in drinking water (1%, ad libitum for 12 weeks) in male C57BL/6J mice promoted a significant reduction in body weight, visceral adipose mass (epididymal and retroperitoneal fat pads) as well as blood glucose levels in mice consuming a HFD. In addition, the amino acid significantly reduced the mRNA expression of the Kidney Injury Marker 1 (KIM-1), P2Y purinoceptor 1 (P2RY1), as well as pro-inflammatory cytokines (IL-6 and TNFα). L-serine administration had no effect on mice consuming a standard chow diet. Collectively, our findings suggest that L-serine is an effective compound for long-term use in animal models and that it ameliorates the metabolic consequences of HFD consumption and reduces the elevated levels of renal pro-inflammatory cytokines occurring in obesity.
- 24 May 2023
- Published by MDPI AG in Nutraceuticals
- Vol. 3 (2) , 262-273
Open AccessTwelve Weeks of Oral L-Serine Supplementation Improves Glucose Tolerance, Reduces Visceral Fat Pads, and Reverses the mRNA Overexpression of Renal Injury Markers KIM-1, IL-6, and TNF-α in a Mouse Model of Obesity
Comorbidities associated with obesity, including diabetes and kidney diseases, greatly increase mortality rates and healthcare costs in obese patients. Studies in animal models and clinical trials have demonstrated that L-serine supplementation is a safe and effective therapeutic approach that ameliorates the consequences of obesity. However, little is known about the effects of L-Serine supplementation following high-fat diet (HFD) consumption and its role in the mRNA expression of markers of kidney injury. We provide a descriptive action by which L-serine administration ameliorated the consequences of HFD consumption in relation to weight loss, glucose homeostasis as well as renal mRNA expression of markers of kidney injury. Our results indicated that L-Serine supplementation in drinking water (1%, ad libitum for 12 weeks) in male C57BL/6J mice promoted a significant reduction in body weight, visceral adipose mass (epididymal and retroperitoneal fat pads) as well as blood glucose levels in mice consuming a HFD. In addition, the amino acid significantly reduced the mRNA expression of the Kidney Injury Marker 1 (KIM-1), P2Y purinoceptor 1 (P2RY1), as well as pro-inflammatory cytokines (IL-6 and TNFα). L-serine administration had no effect on mice consuming a standard chow diet. Collectively, our findings suggest that L-serine is an effective compound for long-term use in animal models and that it ameliorates the metabolic consequences of HFD consumption and reduces the elevated levels of renal pro-inflammatory cytokines occurring in obesity.
- Open Access
Synbiotics as Supplemental Therapy for the Alleviation of Chemotherapy-Associated Symptoms in Patients with Solid Tumours
Chemotherapy is still the first line of treatment for most cancer patients. Patients receiving chemotherapy are generally prone to infections, which result in complications, such as sepsis, mucositis, colitis, and diarrhoea. Several nutritional approaches have been trialled to counter the chemotherapy-associated side effects in cancer patients, but none have yet been approved for routine clinical use. One of the approaches to reduce or avoid chemotherapy-associated complications is to restore the gut microbiota. Gut microbiota is essential for the healthy functioning of the immune system, metabolism, and the regulation of other molecular responses in the body. Chemotherapy erodes the mucosal layer of the gastrointestinal tract and results in the loss of gut microbiota. One of the ways to restore the gut microbiota is through the use of probiotics. Probiotics are the ‘good’ bacteria that may provide health benefits if consumed in appropriate amounts. Some studies have highlighted that the consumption of probiotics in combination with prebiotics, known as synbiotics, may provide better health benefits when compared to probiotics alone. This review discusses the different nutritional approaches that have been studied in an attempt to combat chemotherapy-associated side effects in cancer patients with a particular focus on the use of pre-, pro- and synbiotics.
Open AccessSynbiotics as Supplemental Therapy for the Alleviation of Chemotherapy-Associated Symptoms in Patients with Solid Tumours
Chemotherapy is still the first line of treatment for most cancer patients. Patients receiving chemotherapy are generally prone to infections, which result in complications, such as sepsis, mucositis, colitis, and diarrhoea. Several nutritional approaches have been trialled to counter the chemotherapy-associated side effects in cancer patients, but none have yet been approved for routine clinical use. One of the approaches to reduce or avoid chemotherapy-associated complications is to restore the gut microbiota. Gut microbiota is essential for the healthy functioning of the immune system, metabolism, and the regulation of other molecular responses in the body. Chemotherapy erodes the mucosal layer of the gastrointestinal tract and results in the loss of gut microbiota. One of the ways to restore the gut microbiota is through the use of probiotics. Probiotics are the ‘good’ bacteria that may provide health benefits if consumed in appropriate amounts. Some studies have highlighted that the consumption of probiotics in combination with prebiotics, known as synbiotics, may provide better health benefits when compared to probiotics alone. This review discusses the different nutritional approaches that have been studied in an attempt to combat chemotherapy-associated side effects in cancer patients with a particular focus on the use of pre-, pro- and synbiotics.
- Open Access
- 4 November 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (11) , 2383
Oral Macrocystis pyrifera Fucoidan Administration Exhibits Anti-Inflammatory and Antioxidant Properties and Improves DSS-Induced Colitis in C57BL/6J Mice
Inflammatory bowel disease (IBD) is a complex and multifactorial disorder characterised by relapsing and remitting inflammation of the intestinal tract. Oxidative stress (OS) is the result of an imbalance between production and accumulation of reactive oxygen species (ROS), which has been associated with inflammatory responses and implicated in the exacerbation of IBD. Fucoidan, a sulfated polysaccharide from brown seaweed, is a well-known anti-inflammatory agent and emerging evidence indicates that fucoidan extracts from Macrocystis pyrifera (MPF and DP-MPF) may also modulate oxidative stress. This study investigated the impact of fucoidan extracts, MPF and DP-MPF in a dextran sodium sulphate (DSS)-induced mouse model of acute colitis. 3% DSS was administered in C57BL/6J male mice over a period of 7 days, and MPF and DP-MPF were co-administered orally at a dose of 400 mg/kg body weight. Our results indicated that MPF and DP-MPF significantly prevented body weight loss, improved the disease activity index (DAI), restored colon lengths, reduced the wet colon weight, reduced spleen enlargement, and improved the overall histopathological score. Consistent with the reported anti-inflammatory functions, fucoidan extracts, MPF and DP-MPF significantly reduced the colonic levels of myeloperoxidase (MPO), nitric oxide (NO), malondialdehyde (MDA) and increased the levels of antioxidant enzymes, superoxide dismutase (SOD) and catalase (CAT). In addition, MPF and DP-MPF significantly inhibited levels of pro-inflammatory cytokines in colon-derived tissues. Collectively, our results indicate that MPF and DP-MPF exhibited anti-inflammatory and antioxidant effects representing a promising therapeutic strategy for the cure of IBD.
- 4 November 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (11) , 2383
Open AccessOral Macrocystis pyrifera Fucoidan Administration Exhibits Anti-Inflammatory and Antioxidant Properties and Improves DSS-Induced Colitis in C57BL/6J Mice
Inflammatory bowel disease (IBD) is a complex and multifactorial disorder characterised by relapsing and remitting inflammation of the intestinal tract. Oxidative stress (OS) is the result of an imbalance between production and accumulation of reactive oxygen species (ROS), which has been associated with inflammatory responses and implicated in the exacerbation of IBD. Fucoidan, a sulfated polysaccharide from brown seaweed, is a well-known anti-inflammatory agent and emerging evidence indicates that fucoidan extracts from Macrocystis pyrifera (MPF and DP-MPF) may also modulate oxidative stress. This study investigated the impact of fucoidan extracts, MPF and DP-MPF in a dextran sodium sulphate (DSS)-induced mouse model of acute colitis. 3% DSS was administered in C57BL/6J male mice over a period of 7 days, and MPF and DP-MPF were co-administered orally at a dose of 400 mg/kg body weight. Our results indicated that MPF and DP-MPF significantly prevented body weight loss, improved the disease activity index (DAI), restored colon lengths, reduced the wet colon weight, reduced spleen enlargement, and improved the overall histopathological score. Consistent with the reported anti-inflammatory functions, fucoidan extracts, MPF and DP-MPF significantly reduced the colonic levels of myeloperoxidase (MPO), nitric oxide (NO), malondialdehyde (MDA) and increased the levels of antioxidant enzymes, superoxide dismutase (SOD) and catalase (CAT). In addition, MPF and DP-MPF significantly inhibited levels of pro-inflammatory cytokines in colon-derived tissues. Collectively, our results indicate that MPF and DP-MPF exhibited anti-inflammatory and antioxidant effects representing a promising therapeutic strategy for the cure of IBD.
- Open Access
- 18 October 2022
- Published by MDPI AG in Endocrines
- Vol. 3 (4) , 641-653
The Anti-Obesity Compound Asperuloside Reduces Inflammation in the Liver and Hypothalamus of High-Fat-Fed Mice
Obesity produces a systemic low-grade inflammation associated with many adverse health conditions and, as we recently learned, with complications of COVID-19. Functional studies in animal models have demonstrated that asperuloside, an iridoid glycoside found in many medicinal plants, has produced promising anti-obesity results. However, the safety profile and the anti-inflammatory properties of asperuloside remain unknown. Here, we confirmed the previously reported anti-obesity properties of asperuloside, and, importantly, we performed toxicity studies assessing cell viability providing a dose reference for future animal experiments. Asperuloside significantly reduced blood levels of leptin and the mRNA levels of orexigenic peptides, such as NPY and AgRP in mice consuming HFD, with no effect on mice eating a standard chow diet. In addition, our results indicate that ASP reduced both hypothalamic and hepatic mRNA levels of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α as well as the blood levels of plasminogen activator inhibitor-1 (PAI-1), which are known to play a major role in the development of insulin resistance and cardiovascular complications. Collectively, our findings suggest that asperuloside is a safe compound for long-term use in animal models and that it reduces the elevated levels of pro-inflammatory cytokines occurring in obesity.
- 18 October 2022
- Published by MDPI AG in Endocrines
- Vol. 3 (4) , 641-653
Open AccessThe Anti-Obesity Compound Asperuloside Reduces Inflammation in the Liver and Hypothalamus of High-Fat-Fed Mice
Obesity produces a systemic low-grade inflammation associated with many adverse health conditions and, as we recently learned, with complications of COVID-19. Functional studies in animal models have demonstrated that asperuloside, an iridoid glycoside found in many medicinal plants, has produced promising anti-obesity results. However, the safety profile and the anti-inflammatory properties of asperuloside remain unknown. Here, we confirmed the previously reported anti-obesity properties of asperuloside, and, importantly, we performed toxicity studies assessing cell viability providing a dose reference for future animal experiments. Asperuloside significantly reduced blood levels of leptin and the mRNA levels of orexigenic peptides, such as NPY and AgRP in mice consuming HFD, with no effect on mice eating a standard chow diet. In addition, our results indicate that ASP reduced both hypothalamic and hepatic mRNA levels of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α as well as the blood levels of plasminogen activator inhibitor-1 (PAI-1), which are known to play a major role in the development of insulin resistance and cardiovascular complications. Collectively, our findings suggest that asperuloside is a safe compound for long-term use in animal models and that it reduces the elevated levels of pro-inflammatory cytokines occurring in obesity.
- 13 May 2022
- Published by Wiley in The FASEB Journal
- Vol. 36 (S1)
Fucoidan as an inhibitor of pro‐inflammatory cytokines: Potential candidate for treating inflammatory‐related conditions
Fucoidans are bio‐functional sulfated, complex, fucose‐rich polymers found in brown seaweeds. Fucoidans are favourable worldwide, particularly amongst the nutraceutical and pharmaceutical industry due to their promising therapeutic effects. Their applaudable biological functions are attributed to their unique biological structure. Fucoidans have been shown to have multiple biological activities, including anti‐inflammatory effects, and are recognised to inhibit inflammatory processes via several pathways such as enzyme inhibition and selectin blockade, and have demonstrated inhibition of inflammatory pathologies in‐vivo . Inflammation is a part of the complex biological response of living systems against harmful stimuli and is involved in the pathogenesis of diverse diseases, including arthritis, Inflammatory Bowel diseases, cancer, and allergies. In this current research, several fucoidan extracts from Undaria pinnatifida, Fucus vesiculosus, Macrocystis pyrifera, Ascophyllum nodosum, and Laminaria japonica were assessed for inhibition of pro‐inflammatory cytokine production (TNF‐α, IL‐1β, and IL‐6) in LPS induced human macrophage cell line (THP‐1) and human peripheral blood mononuclear cells (PBMCs). Furthermore, we also sought to catalogue these extracts based on their anti‐inflammatory effects in the current in‐vitro cell model. Material and methods: MTT cell viability assay was performed to assess the cytotoxicity of fucoidan extracts. Furthermore, a dose‐response for fucoidan extracts was performed in LPS induced THP‐1 cells and PBMCs after pre‐treatment for 24 hours and levels of TNF‐α, IL‐1β, and IL‐6 cytokines were measured using Enzyme‐Linked Immunosorbent Assay (ELISA) . Results: MTT cell viability assay revealed that fucoidan extracts displayed no signs of cytotoxicity in THP‐1 cells and PBMCs after incubation of 48 hours. Sandwich ELISA results exhibited that all fucoidan extracts reduced cytokine production in LPS stimulated PBMCs and human THP‐1 cells in a dose‐dependent fashion. Notably, the lower molecular fucoidan ( 5‐30 kDa ) extract from Macrocystis pyrifera was a highly effective inhibitor of pro‐inflammatory cytokine at lower concentrations. Fucoidan extracts from all species demonstrated significant anti‐inflammatory effects; however, the lower molecular weight extracts showed maximal effects at low concentrations. These observations on various fucoidan extracts offer insight into strategies that improve their efficacy against inflammation‐related pathology. Conclusion: We have successfully catalogued many fucoidan extracts based on their efficacy in LPS induced macrophages and PBMCs in down‐regulating major pro‐inflammatory cytokines (TNF‐α, IL‐1β, and IL‐6), potential targets in human inflammatory conditions. Further investigation would provide additional insights about the mechanism of action to test for therapeutic applications as an anti‐inflammatory medication.
- 13 May 2022
- Published by Wiley in The FASEB Journal
- Vol. 36 (S1)
Fucoidan as an inhibitor of pro‐inflammatory cytokines: Potential candidate for treating inflammatory‐related conditions
Fucoidans are bio‐functional sulfated, complex, fucose‐rich polymers found in brown seaweeds. Fucoidans are favourable worldwide, particularly amongst the nutraceutical and pharmaceutical industry due to their promising therapeutic effects. Their applaudable biological functions are attributed to their unique biological structure. Fucoidans have been shown to have multiple biological activities, including anti‐inflammatory effects, and are recognised to inhibit inflammatory processes via several pathways such as enzyme inhibition and selectin blockade, and have demonstrated inhibition of inflammatory pathologies in‐vivo . Inflammation is a part of the complex biological response of living systems against harmful stimuli and is involved in the pathogenesis of diverse diseases, including arthritis, Inflammatory Bowel diseases, cancer, and allergies. In this current research, several fucoidan extracts from Undaria pinnatifida, Fucus vesiculosus, Macrocystis pyrifera, Ascophyllum nodosum, and Laminaria japonica were assessed for inhibition of pro‐inflammatory cytokine production (TNF‐α, IL‐1β, and IL‐6) in LPS induced human macrophage cell line (THP‐1) and human peripheral blood mononuclear cells (PBMCs). Furthermore, we also sought to catalogue these extracts based on their anti‐inflammatory effects in the current in‐vitro cell model. Material and methods: MTT cell viability assay was performed to assess the cytotoxicity of fucoidan extracts. Furthermore, a dose‐response for fucoidan extracts was performed in LPS induced THP‐1 cells and PBMCs after pre‐treatment for 24 hours and levels of TNF‐α, IL‐1β, and IL‐6 cytokines were measured using Enzyme‐Linked Immunosorbent Assay (ELISA) . Results: MTT cell viability assay revealed that fucoidan extracts displayed no signs of cytotoxicity in THP‐1 cells and PBMCs after incubation of 48 hours. Sandwich ELISA results exhibited that all fucoidan extracts reduced cytokine production in LPS stimulated PBMCs and human THP‐1 cells in a dose‐dependent fashion. Notably, the lower molecular fucoidan ( 5‐30 kDa ) extract from Macrocystis pyrifera was a highly effective inhibitor of pro‐inflammatory cytokine at lower concentrations. Fucoidan extracts from all species demonstrated significant anti‐inflammatory effects; however, the lower molecular weight extracts showed maximal effects at low concentrations. These observations on various fucoidan extracts offer insight into strategies that improve their efficacy against inflammation‐related pathology. Conclusion: We have successfully catalogued many fucoidan extracts based on their efficacy in LPS induced macrophages and PBMCs in down‐regulating major pro‐inflammatory cytokines (TNF‐α, IL‐1β, and IL‐6), potential targets in human inflammatory conditions. Further investigation would provide additional insights about the mechanism of action to test for therapeutic applications as an anti‐inflammatory medication.
- Open Access
- 11 December 2021
- Published by MDPI AG in Marine Drugs
- Vol. 19 (12) , 702
Anti-Inflammatory Activity of Fucoidan Extracts In Vitro
Fucoidans are sulfated, complex, fucose-rich polymers found in brown seaweeds. Fucoidans have been shown to have multiple bioactivities, including anti-inflammatory effects, and are known to inhibit inflammatory processes via a number of pathways such as selectin blockade and enzyme inhibition, and have demonstrated inhibition of inflammatory pathologies in vivo. In this current investigation, fucoidan extracts from Undaria pinnatifida, Fucus vesiculosus, Macrocystis pyrifera, Ascophyllum nodosum, and Laminaria japonica were assessed for modulation of pro-inflammatory cytokine production (TNF-α, IL-1β, and IL-6) by human peripheral blood mononuclear cells (PBMCs) and in a human macrophage line (THP-1). Fucoidan extracts exhibited no signs of cytotoxicity in THP-1 cells after incubation of 48 h. Additionally, all fucoidan extracts reduced cytokine production in LPS stimulated PBMCs and human THP-1 cells in a dose-dependent fashion. Notably, the 5–30 kDa subfraction from Macrocystis pyrifera was a highly effective inhibitor at lower concentrations. Fucoidan extracts from all species had significant anti-inflammatory effects, but the lowest molecular weight subfractions had maximal effects at low concentrations. These observations on various fucoidan extracts offer insight into strategies that improve their efficacy against inflammation-related pathology. Further studies should be conducted to elucidate the mechanism of action of these extracts.
- 11 December 2021
- Published by MDPI AG in Marine Drugs
- Vol. 19 (12) , 702
Open AccessAnti-Inflammatory Activity of Fucoidan Extracts In Vitro
Fucoidans are sulfated, complex, fucose-rich polymers found in brown seaweeds. Fucoidans have been shown to have multiple bioactivities, including anti-inflammatory effects, and are known to inhibit inflammatory processes via a number of pathways such as selectin blockade and enzyme inhibition, and have demonstrated inhibition of inflammatory pathologies in vivo. In this current investigation, fucoidan extracts from Undaria pinnatifida, Fucus vesiculosus, Macrocystis pyrifera, Ascophyllum nodosum, and Laminaria japonica were assessed for modulation of pro-inflammatory cytokine production (TNF-α, IL-1β, and IL-6) by human peripheral blood mononuclear cells (PBMCs) and in a human macrophage line (THP-1). Fucoidan extracts exhibited no signs of cytotoxicity in THP-1 cells after incubation of 48 h. Additionally, all fucoidan extracts reduced cytokine production in LPS stimulated PBMCs and human THP-1 cells in a dose-dependent fashion. Notably, the 5–30 kDa subfraction from Macrocystis pyrifera was a highly effective inhibitor at lower concentrations. Fucoidan extracts from all species had significant anti-inflammatory effects, but the lowest molecular weight subfractions had maximal effects at low concentrations. These observations on various fucoidan extracts offer insight into strategies that improve their efficacy against inflammation-related pathology. Further studies should be conducted to elucidate the mechanism of action of these extracts.
- Open Access
- 29 April 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Metabolic Changes Induced by Purinergic Signaling: Role in Food Intake
The purinergic signalling has a well-established role in the regulation of energy homeostasis, but there is growing evidence of its implication in the control of food intake. In this review, we provide an integrative view of the molecular mechanisms leading to changes in feeding behaviour within hypothalamic neurons following purinergic receptor activation. We also highlight the importance of purinergic signalling in metabolic homeostasis and the possibility of targeting its receptors for therapeutic purposes.
- 29 April 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessMetabolic Changes Induced by Purinergic Signaling: Role in Food Intake
The purinergic signalling has a well-established role in the regulation of energy homeostasis, but there is growing evidence of its implication in the control of food intake. In this review, we provide an integrative view of the molecular mechanisms leading to changes in feeding behaviour within hypothalamic neurons following purinergic receptor activation. We also highlight the importance of purinergic signalling in metabolic homeostasis and the possibility of targeting its receptors for therapeutic purposes.
- Open Access
- 13 April 2021
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 12
Asperuloside Enhances Taste Perception and Prevents Weight Gain in High-Fat Fed Mice
Asperuloside is an iridoid glycoside found in many medicinal plants that has produced promising anti-obesity results in animal models. In previous studies, three months of asperuloside administration reduced food intake, body weight, and adipose masses in rats consuming a high fat diet (HFD). However, the mechanisms by which asperuloside exerts its anti-obesity properties were not clarified. Here, we investigated homeostatic and nutrient-sensing mechanisms regulating food intake in mice consuming HFD. We confirmed the anti-obesity properties of asperuloside and, importantly, we identified some mechanisms that could be responsible for its therapeutic effect. Asperuloside reduced body weight and food intake in mice consuming HFD by 10.5 and 12.8% respectively, with no effect on mice eating a standard chow diet. Fasting glucose and plasma insulin were also significantly reduced. Mechanistically, asperuloside significantly reduced hypothalamic mRNA ghrelin, leptin, and pro-opiomelanocortin in mice consuming HFD. The expression of fat lingual receptors (CD36, FFAR1-4), CB1R and sweet lingual receptors (TAS1R2-3) was increased almost 2-fold by the administration of asperuloside. Our findings suggest that asperuloside might exert its therapeutic effects by altering nutrient-sensing receptors in the oral cavity as well as hypothalamic receptors involved in food intake when mice are exposed to obesogenic diets. This signaling pathway is known to influence the subtle hypothalamic equilibrium between energy homeostasis and reward-induced overeating responses. The present pre-clinical study demonstrated that targeting the gustatory system through asperuloside administration could represent a promising and effective new anti-obesity strategy.
- 13 April 2021
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 12
Open AccessAsperuloside Enhances Taste Perception and Prevents Weight Gain in High-Fat Fed Mice
Asperuloside is an iridoid glycoside found in many medicinal plants that has produced promising anti-obesity results in animal models. In previous studies, three months of asperuloside administration reduced food intake, body weight, and adipose masses in rats consuming a high fat diet (HFD). However, the mechanisms by which asperuloside exerts its anti-obesity properties were not clarified. Here, we investigated homeostatic and nutrient-sensing mechanisms regulating food intake in mice consuming HFD. We confirmed the anti-obesity properties of asperuloside and, importantly, we identified some mechanisms that could be responsible for its therapeutic effect. Asperuloside reduced body weight and food intake in mice consuming HFD by 10.5 and 12.8% respectively, with no effect on mice eating a standard chow diet. Fasting glucose and plasma insulin were also significantly reduced. Mechanistically, asperuloside significantly reduced hypothalamic mRNA ghrelin, leptin, and pro-opiomelanocortin in mice consuming HFD. The expression of fat lingual receptors (CD36, FFAR1-4), CB1R and sweet lingual receptors (TAS1R2-3) was increased almost 2-fold by the administration of asperuloside. Our findings suggest that asperuloside might exert its therapeutic effects by altering nutrient-sensing receptors in the oral cavity as well as hypothalamic receptors involved in food intake when mice are exposed to obesogenic diets. This signaling pathway is known to influence the subtle hypothalamic equilibrium between energy homeostasis and reward-induced overeating responses. The present pre-clinical study demonstrated that targeting the gustatory system through asperuloside administration could represent a promising and effective new anti-obesity strategy.
- Open Access
- 19 April 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (S1) , 1
Asperuloside reduces food intake and body weight via downregulation of orexigenic hypothalamic signalling in a mouse model of metabolic syndrome.
Controlling the urge to eat requires adequate integration of hypothalamic neuropeptides regulating energy balance processes with dopaminergic circuits in the mesolimbic pathway. Disruption of this signalling alters the hedonic control of reward‐driven food intake contributing to obesity. Our study aimed to understand the mechanism of action of the novel anti‐obesity compound, asperuloside (ASP), and whether ASP treatment could be used as safe weight loss treatment. Mice were fed with a 45% high fat diet (HFD) and concurrently treated with ASP for 12 weeks. ASP reduced significantly (10.50%, p<0.05) final body weight of HFD mice compared to their control group. The effects of ASP reached significance after 5 weeks of treatment and were maintained throughout the experiment. Over the experimental period, the compound induced a significant daily energy intake reduction (12.8%, p<0.05) in mice consuming HFD compared to their control group. When standardised by body weight, visceral adipose mass was increased by the effect of HFD and significantly reduced by ASP treatment (35%, p<0.05). Orexigenic hypothalamic genes including NPY and ARGP, as well as important receptors involved in the control of food intake such as ghrelin, leptin and cannabinoid receptors, were significantly (p<0.05) downregulated by ASP treatment. These results suggest that ASP might induce weight loss plausibly via downregulation of hypothalamic signalling and support ASP candidacy as a potential and safe drug for the treatment of obesity.
- 19 April 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (S1) , 1
Open AccessAsperuloside reduces food intake and body weight via downregulation of orexigenic hypothalamic signalling in a mouse model of metabolic syndrome.
Controlling the urge to eat requires adequate integration of hypothalamic neuropeptides regulating energy balance processes with dopaminergic circuits in the mesolimbic pathway. Disruption of this signalling alters the hedonic control of reward‐driven food intake contributing to obesity. Our study aimed to understand the mechanism of action of the novel anti‐obesity compound, asperuloside (ASP), and whether ASP treatment could be used as safe weight loss treatment. Mice were fed with a 45% high fat diet (HFD) and concurrently treated with ASP for 12 weeks. ASP reduced significantly (10.50%, p<0.05) final body weight of HFD mice compared to their control group. The effects of ASP reached significance after 5 weeks of treatment and were maintained throughout the experiment. Over the experimental period, the compound induced a significant daily energy intake reduction (12.8%, p<0.05) in mice consuming HFD compared to their control group. When standardised by body weight, visceral adipose mass was increased by the effect of HFD and significantly reduced by ASP treatment (35%, p<0.05). Orexigenic hypothalamic genes including NPY and ARGP, as well as important receptors involved in the control of food intake such as ghrelin, leptin and cannabinoid receptors, were significantly (p<0.05) downregulated by ASP treatment. These results suggest that ASP might induce weight loss plausibly via downregulation of hypothalamic signalling and support ASP candidacy as a potential and safe drug for the treatment of obesity.
- 1 January 2020
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 315, 108911
Emerging therapeutic potential of the iridoid molecule, asperuloside: A snapshot of its underlying molecular mechanisms
- 1 January 2020
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 315, 108911
Emerging therapeutic potential of the iridoid molecule, asperuloside: A snapshot of its underlying molecular mechanisms